This week, our President and Managing Director, Jennifer Che, attended the Asia Summit for Global Health at the Hong Kong Convention and Exhibition Centre (HKCEC). She was truly impressed by the variety of health-related start-ups, projects, prototypes, and collaborations showcased at the event. The advancements in therapeutics, traditional Chinese medicine, diagnostics, surgical equipment, robotics, and AI solutions highlighted the dynamic biotech landscape of Hong Kong today—a stark contrast to when she first arrived.

Jennifer particularly noted the remarkable initiatives emerging from the InnoHK Centres, which stem from collaborations between local and international universities. Reflecting on the event, she echoed Nancy Ip's sentiment at the HKUST reception: “We can’t do it alone. The most important thing is to collaborate.” This collaborative spirit is vital for driving innovation and improving global health outcomes.

我们的过去活动

Recommended Insights

How will Civil Cases Work under the Patent Linkage Provision in the New Chinese Patent Law?

2020年11月20日
The Supreme People’s Court has just issued draft regulations for comment regarding how new Article 76 will work in conjunction with civil procedure law. The period to submit comments ends December 14, 2020, and the final version will come into force June 1, 2021, together with the new Chinese Patent Law. The Backdrop: New Chinese […]

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

2022年9月21日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

Foreigners Beware: China Proposes Requiring IP Made Using Exported Chinese Genetic Resources to be Co-Owned by Chinese Collaborators

2023年3月22日
Proposed Examination Guidelines for the New Chinese Patent Law – Topic 2: Genetic Resource Restriction How Will the Tightened Genetic Resource Restrictions Affect Your IP In 2019-2021, China’s Ministry of Science and Technology (“MOST”, or the Science Ministry) established several laws and regulations with respect to biosafety1 and human genetic resources management2 (collectively referred as […]
Top crossarrow-right